BCL6 Antibody | 6985

BCL6 Antibody | 6985 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: BCL6 antibody was raised against an 18 amino acid synthetic peptide near the center of human BCL6.
The immunogen is located within amino acids 370 - 420 of BCL6.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB

Application: BCL6 antibody can be used for detection of BCL6 by Western blot at 1 μg/mL.
Antibody validated: Western Blot in rat samples. All other applications and species not yet tested.

Specificiy: Three alternatively spliced transcript variants have been observed

Positive Control 1: Cat. No. 1462 - Rat Lung Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 78 kDa

Validation: N/A

Isoform: N/A

Purification: BCL6 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: BCL6 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: BCL6 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: BCL6 Antibody: BCL5, LAZ3, BCL6A, ZNF51, ZBTB27, BCL5, B-cell lymphoma 6 protein, B-cell lymphoma 5 protein, BCL-6

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML) .